You forget that the unvaccinated can develop broad-based natural T-cell immunity when exposed to the whole virus, as opposed to narrow-based T-cell immunity when exposed to a single type of (in the case of the mRNA vaccines) spike protein. In the latter case, you get a very much smaller "library" of epitopes which can recognize the spike protein and one- or two-base pair mutations - and not mutations which differ by 30 base pairs as in the South African '351 variant. Tests were done of people who had recovered from the 2003 SARS epidemic (caused by SARS-CoV-1) in 2020, and it was found that they were immune to SARS-CoV-2, which causes COVID. SARS-CoV-1 differs from SARS-CoV-2 by around 30 base pairs or so, including base pairs corresponding to a furin cleavage site, which makes for tighter binding to ACE-2 receptors, which makes SARS-CoV-2 more infective. The immunity still existed, because the epitope "library" was still large enough to recognize SARS-CoV-2. This "library" included epitopes which recognize nucleocapsid ("N") proteins, and membrane ("M") proteins, as well as spike ("S") proteins. And the tendency to mutate is very much more likely for the spike proteins. So you've got the situation reversed, the vaccinated are more likely to generate variants where the spike protein has mutated to escape the limited "library" of epitopes created by the mRNA vaccines. The unvaccinated population with broad-based T-cell immunity are more likely to inhibit spread of these variants than the population vaccinated to produce narrow-based T-cell immunity based on spike proteins. Without this narrow-based immunity, with enough of the population developing broad-based T-cell immunity, it's likely that the epidemic caused by SARS-CoV-2 would disappear, just like the SARS epidemic caused by SARS-CoV-1 did by 2005, instead of becoming endemic for the next ten years, with a tremendously profitable game of whack-a-mole for vaccine producers, companies producing blockchain vaccine passports, and the rest. See
https://www.nature.com/article...